Receive our newsletter – data, insights and analysis delivered to you
June 24, 2009

Javelin Completes Safety Study Of Dyloject Pain Drug

Javelin Pharmaceuticals has announced successfully meeting objectives during an open label, multi-dose, multi-day, observational safety study of Dyloject, a treatment for patients with acute post-operative pain. The objective of the study was to evaluate the safety of Dyloject, followi

By cms admin

Javelin Pharmaceuticals has announced successfully meeting objectives during an open label, multi-dose, multi-day, observational safety study of Dyloject, a treatment for patients with acute post-operative pain.

The objective of the study was to evaluate the safety of Dyloject, following IV bolus administration of multiple doses over multiple days in patients aged 18 to 85, with acute post-operative pain.

The company now plans to file a New Drug application (NDA) for Dyloject in the US.

Javelin vice-president of clinical research Eric Lang said that 856 patients successfully completed the study, receiving at least eight doses of Dyloject.

“Javelin now has comprehensive safety data on more than 1,700 patients in our Integrated Summary of Safety for our NDA submission,” Lang said. “We are on track to file a high-quality NDA for Dyloject this autumn.”

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU